 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C21H24N4O2 |
| Molar mass | 364.449 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
ADB-BINACA (also known asADMB-BZINACA using EMCDDA naming standards[1]) is acannabinoiddesigner drug that has been found as an ingredient in somesynthetic cannabis products.[2] It was originally developed byPfizer as a potentialanalgesic, and is a potentagonist of theCB1 receptor with abinding affinity (Ki) of 0.33 nM and anEC50 of 14.7 nM.[3]
The analogue with a 1-butyl substitution on the indazole ring rather than 1-benzyl has also been sold as a designer drug under the name ADB-BINACA, but is now more commonly referred to asADB-BUTINACA to avoid confusion with the benzyl compound.[4][5][6][7][8] It is a similarly potent CB1 agonist, with a binding affinity of 0.29nM for CB1 and 0.91nM for CB2, and an EC50 of 6.36 nM for CB1.[9][10]
